Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.66 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13889936 | 0.96 | CALCRL (0.68) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL1206758 | 0.95 | CALCRL (0.62) | CALCRLRAMP1 | |
| SCHEMBL126002 | 0.92 | CALCRL (0.65) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL1205657 | 0.92 | CALCRL (0.65) | CALCRLRAMP1CYP3A4 | |
| Bromide SCHEMBL148098 | 0.92 | CALCRL (0.64) | CALCRLRAMP1CYP3A4 | |
| Hydrochloric Acid SCHEMBL147355 | 0.92 | CALCRL (0.64) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2086979 | 0.91 | CALCRL (0.77) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2086981 | 0.91 | CALCRL (0.77) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13331941 | 0.91 | CALCRL (0.72) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2164789 | 0.91 | CALCRL (0.64) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551987-B2 | Crystalline ethyl 4-[4-[(2R)-3-[4-amino-3-chloro-5-(trifluoromethyl)phenyl]-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-piperidine-1-acetate difumarate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-20120058994-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058994-A1 | NOVEL COMPOUNDS | FH, FAH, SLC9B2 | CALCRL 4195/4885RAMP1 4474/4885CYP3A4 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.